While current approaches for treating BRAF V600-mutant solid tumors vary based on cancer type, the FDA granted accelerated approval for the use of BRAFi dabrafenib in combination with MEKi trametinib for the treatment of all unresectable or metastatic BRAF V600E-mutant solid tumors except for CRC in June 2022. This evidence concerns the gene BRAF and colorectal carcinoma.